Paper in Adv Pharmacol Pharm

We are pleased to share findings from our recent pilot study published in Advances in Pharmacology and Pharmacy, which provides new insights into the pharmacokinetics of inhaled molecular hydrogen in healthy humans.

Molecular hydrogen has emerged as a promising therapeutic gas, with potential applications in a range of acute and chronic conditions. However, despite increasing interest, human data on hydrogen pharmacokinetics remain limited, particularly with respect to optimal dosing and exposure duration.

In this study, healthy participants completed three separate inhalation sessions lasting 15, 30, and 45 minutes. Blood dihydrogen concentrations were measured at multiple time points following each exposure to characterize concentration–time profiles. The analysis revealed clear, duration-dependent differences in hydrogen uptake and systemic exposure.

A 45-minute inhalation protocol resulted in faster peak blood concentrations (lower Tmax) and greater overall exposure (higher AUC) compared with shorter inhalation periods. Based on these data, the minimum effective blood concentration of dihydrogen was estimated to range between 0.42 and 1.05 µg/L.

Overall, the findings demonstrate a dose-response relationship between inhalation duration and hydrogen absorption and provide preliminary pharmacokinetic benchmarks that may help inform the design of future clinical studies and therapeutic applications of inhaled hydrogen.